Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases
NCT06676917 · MedSIR · PHASE2 · withdrawn · last registry update 2025-08-08 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The clinical trial has not been approved by the regulatory authority.” | Open Targets' class: regulatory | Registry record, MedSIR |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACSTD2 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-09Also stopped (terminated): Regeneron Pharmaceuticals, vidutolimod + cemiplimab (NCT04916002)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-04-28Also stopped (withdrawn): National Cancer Institute (NCI), Tarlatamab + Sacituzumab Govitecan (NCT07328490)
- 2025-12-18Phase 3 first posted: AstraZeneca, Datopotamab deruxtecan (Dato-DXd) + Docetaxel (NCT07291037)
- 2025-12-05Results posted on the registry: Regeneron Pharmaceuticals, vidutolimod + cemiplimab (NCT04916002)
- 2025-07-23Results posted on the registry: Daiichi Sankyo, DS-1062a + Docetaxel (NCT04656652)
- 2025-06-13Results posted on the registry: AstraZeneca, Datopotamab Deruxtecan (Dato-DXd) (NCT05460273)
- 2025-01-30Phase 3 first posted: Gilead Sciences, Sacituzumab Govitecan (SG) + Topotecan (NCT06801834)
- 2025-01-14Results posted on the registry: Gilead Sciences, Sacituzumab Govitecan-hziy (SG) + Docetaxel (NCT05089734)
- 2024-08-21Phase 3 first posted: AstraZeneca, Datopotamab Deruxtecan + Rilvegostomig (NCT06564844)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision